Outcomes of high, t(11;14), and standard cytogenetic risk multiple myeloma following early high dose therapy and autologous hematopoietic cell transplantation (SCT).

Abstract

8583 Background: Current cytogenetic risk stratification in newly diagnosed multiple myeloma (NDMM) is not derived from recent patients (pts) treated with novel agents. High dose melphalan and SCT is a preferred management strategy for transplant eligible NDMM pts following novel agent induction. We investigated outcomes of high cytogenetic risk (HR), t(11;14), and standard cytogenetic risk (SR) NDMM treated with early SCT. Methods: Following Mayo Clinic IRB approval and in accordance with the Declaration of Helsinki, all pts treated at Mayo Clinic Rochester with SCT for NDMM between 2003 and 2012 were identified (n = 941). We excluded pts without FISH cytogenetics from diagnosis (dx) and those who did not undergo SCT within 12 months of dx. HR was defined as a composite of mSMART high and intermediate risk abnormalities including del(17p), t(4;14), t(14;20) or t(14;16). Response and progression were defined per IMWG criteria. Overall survival (OS) and progression free survival (PFS) were calculated from ...